Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Trial details
- Registry ID
- NCT02968004
- Phase
- Phase 3
The FDA approved Somatropin (Genotropin) on 16 Oct 1986.
Drug identity checked against registry records
Also recorded as Genotropin
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02968004 | OPK | Phase 3 | Completed | 2019-08Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1986-10-16Day | Somatropin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA019640", "applicant_as_listed_by_fda": "LILLY", "brand_names": ["HUMATROPE"], "active_ingredients": ["SOMATROPIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19861016", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |